PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFezolinetant
Fezolinetant
Veozah (fezolinetant) is a small molecule pharmaceutical. Fezolinetant was first approved as Veozah on 2023-05-12. It is used to treat hot flashes in the USA. The pharmaceutical is active against neuromedin-K receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Veozah
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fezolinetant
Tradename
Company
Number
Date
Products
VEOZAHAstellas PharmaN-216578 RX2023-05-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
veozahNew Drug Application2024-08-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hot flashesD019584
Agency Specific
FDA
EMA
Expiration
Code
FEZOLINETANT, VEOZAH, ASTELLAS
2028-05-12NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Fezolinetant, Veozah, Astellas
94222992034-03-28DS, DPU-3622
99872742034-03-28U-3622
108367682034-03-28U-3621
88717612031-04-04DP
ATC Codes
G: Genito urinary system and sex hormones
G02: Other gynecologicals in atc
G02C: Other gynecologicals in atc
G02CX: Other gynecologicals in atc
G02CX06: Fezolinetant
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hot flashesD01958439113
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MenopauseD008593EFO_0003922N9511
CarcinomaD002277C80.011
Breast neoplasmsD001943EFO_0003869C5011
Carcinoma in situD002278D09.911
Ductal carcinoma breastD01827011
Ductal carcinomaD04458411
Intraductal carcinoma noninfiltratingD002285D05.111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients66
Liver diseasesD008107HP_0002910K70-K7711
Hepatic insufficiencyD04855011
Renal insufficiencyD051437HP_0000083N1911
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFezolinetant
INNfezolinetant
Description
Fezolinetant is a triazolopyrazine that is 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine substituted by 3-methyl-1,2,4-thiadiazol-5-yl, 4-fluorobenzoyl and methyl groups at positions 3, 7, and 8R, respectively. It is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. It has a role as a neurokinin-3 receptor antagonist. It is a member of monofluorobenzenes, a triazolopyrazine, a member of thiadiazoles, a member of benzamides and a tertiary carboxamide.
Classification
Small molecule
Drug classtachykinin (neurokinin) receptor antagonists: NK3 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
Identifiers
PDB
CAS-ID1629229-37-3
RxCUI
ChEMBL IDCHEMBL3608680
ChEBI ID
PubChem CID117604931
DrugBankDB15669
UNII ID83VNE45KXX (ChemIDplus, GSRS)
Target
Agency Approved
TACR3
TACR3
Organism
Homo sapiens
Gene name
TACR3
Gene synonyms
NK3R, TAC3R
NCBI Gene ID
Protein name
neuromedin-K receptor
Protein synonyms
Neurokinin B receptor, neurokinin beta receptor, NK-3 receptor, NK-3R, NK3 receptor, Tachykinin receptor 3
Uniprot ID
Mouse ortholog
Tacr3 (21338)
neuromedin-K receptor (Q9JKN0)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 129 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
326 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use